Mitral Valve Repair in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES (Indications for Mitral Valve Repair):

• Symptomatic severe primary (degenerative) mitral regurgitation (Stage D MR per AHA/ACC staging) with LVEF > 30%

• Asymptomatic severe MR with left ventricular dysfunction: LVEF 30–60% and/or LVESD ≥ 40 mm (Class I indication)

• Asymptomatic severe MR with preserved LV function when repair is highly likely (>95% probability) at an experienced center (Class IIa indication)

• New-onset atrial fibrillation or pulmonary hypertension (resting PASP > 50 mmHg) attributable to severe MR

• Moderate MR (Stage B–C) in patients undergoing concurrent cardiac surgery (e.g., CABG, tricuspid repair, or atrial fibrillation ablation)

• Rheumatic mitral stenosis with pliable, non-calcified leaflets amenable to commissurotomy or open surgical repair

• High surgical risk patients with primary MR who qualify for transcatheter edge-to-edge repair (TEER) via MitraClip or PASCAL device under Heart Team evaluation

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Transthoracic Echocardiography (TTE): baseline assessment of MR severity, mechanism (Carpentier classification: Type I, II, or III), leaflet morphology, annular dimensions, LV size and function, and pulmonary pressures

• Transesophageal Echocardiography (TEE): detailed anatomical mapping of leaflet segments, chordal pathology, and annular calcification; mandatory for surgical planning and intraoperative assessment

• Cardiac CT Angiography (CCTA): pre-operative annular sizing for transcatheter procedures (TEER, transcatheter mitral valve replacement); coronary artery assessment in patients ≥ 45 years or with CAD risk factors

• Coronary Angiography (invasive): to rule out concomitant coronary artery disease in patients requiring combined CABG; standard in patients over 50 years or with typical angina

• Cardiac MRI (CMR): quantification of regurgitant fraction and regurgitant volume when echocardiographic grading is indeterminate; LV volumetric assessment

• 12-lead ECG and 24-hour Holter monitoring: to identify atrial fibrillation, conduction disease, or arrhythmia burden

• Pulmonary Function Tests (PFTs): mandatory pre-operatively to assess respiratory reserve, particularly in patients with longstanding pulmonary hypertension

• Laboratory workup: CBC, coagulation profile (PT/INR/aPTT), comprehensive metabolic panel (renal and hepatic function), HbA1c, lipid profile, thyroid function, blood group and crossmatch, serology (HIV, HBV, HCV)

• STS Risk Score or EuroSCORE II calculation: objective surgical risk stratification

• 6-Minute Walk Test (6MWT): functional capacity assessment

• CONTRAINDICATIONS / UNFAVORABLE FACTORS:

• Severely reduced LVEF (< 30%) with end-stage cardiomyopathy — increased perioperative mortality risk; Heart Team review required

• Heavily calcified mitral annulus (mitral annular calcification, MAC) — significantly impairs ring annuloplasty; may necessitate replacement

• Complex rheumatic MR with rigid, calcified, fused leaflets — repair feasibility reduced; replacement often required

• Active endocarditis with extensive annular destruction or abscess — staged approach may be needed

• Severe irreversible pulmonary hypertension (PVR > 6 Wood units unresponsive to vasodilators) — high perioperative risk

• Prohibitive surgical risk (STS predicted mortality > 8%) without transcatheter alternative — palliative management may be appropriate

• Uncorrected significant coagulopathy or active systemic infection

SURGICAL MITRAL VALVE REPAIR — STANDARD APPROACHES:

1. CONVENTIONAL OPEN-HEART REPAIR (MEDIAN STERNOTOMY)

The traditional and most widely performed approach. The chest is opened via full median sternotomy, and the heart is arrested using cold cardioplegia on cardiopulmonary bypass (CPB). The Carpentier functional classification guides the specific repair technique employed: Type I (normal leaflet motion — annuloplasty alone), Type II (leaflet prolapse/excess motion — resection or chordal techniques), or Type III (restricted leaflet motion — commissurotomy, decalcification, or pericardial augmentation). This approach is preferred in cases requiring concomitant procedures (CABG, tricuspid repair, Cox-Maze IV for AF ablation).

2. MINIMALLY INVASIVE MITRAL VALVE REPAIR (MINI-THORACOTOMY)

A right lateral mini-thoracotomy (4–5 cm incision) with peripheral CPB cannulation via the femoral vessels. The operative field is visualized via a thoracoscopic camera. This approach avoids full sternotomy, resulting in significantly reduced blood loss, lower transfusion rates, shorter ICU and hospital stays, faster return to activities (4–6 weeks vs. 8–12 weeks), superior cosmesis, and equivalent repair durability compared to sternotomy. Recommended by ESC/EACTS guidelines at experienced centers and increasingly preferred for isolated mitral valve disease.

3. ROBOTIC-ASSISTED MITRAL VALVE REPAIR (da Vinci Surgical System)

The most technologically advanced surgical platform, available at select GAF Healthcare partner centers in India and the UAE. The surgeon operates from a console, using robotic arms with 7 degrees of freedom and 10× magnification via a 3D high-definition camera introduced through 8–12 mm ports. Tremor filtration and enhanced dexterity allow for precise leaflet resection, neochordal implantation, and ring annuloplasty with the smallest possible incisions (no chest opening required). Clinical outcomes — including repair rates, long-term durability, and valve competence — are equivalent to or superior to open surgery at experienced robotic programs, with superior recovery profiles.

CORE MITRAL REPAIR TECHNIQUES (applicable across all approaches):

• QUADRANGULAR / TRIANGULAR RESECTION: Resection of the prolapsing posterior leaflet segment (most commonly P2) with sliding leaflet plasty and reconstruction — the most durable technique for fibroelastic deficiency.

• ARTIFICIAL CHORDAE (NEOCHORDOPLASTY) using expanded polytetrafluoroethylene (ePTFE / Gore-Tex) sutures: Replacement of ruptured or elongated native chordae tendineae. Particularly preferred for anterior leaflet prolapse, where resection is anatomically limited. The 'loop technique' and 'length determination techniques' allow precise geometric reconstruction.

• RING ANNULOPLASTY: Implantation of a rigid, semi-rigid, or flexible annuloplasty ring or band to correct annular dilatation, restore the saddle-shaped annular geometry, and provide a durable scaffold for the repair. Commonly used rings include Carpentier-Edwards Physio II, Medtronic Profile 3D, and St. Jude Tailor rings. Ring selection depends on annular size (measured intraoperatively), pathology, and surgeon preference.

• ALFIERI EDGE-TO-EDGE STITCH: Suture approximation of the anterior and posterior leaflet at the point of regurgitation, creating a double-orifice valve. Used as an adjunct in complex repairs or as the basis for transcatheter TEER.

• COMMISSUROTOMY AND LEAFLET AUGMENTATION: Used in rheumatic disease — division of fused commissures, decalcification of leaflets, and reconstruction with autologous pericardial or bovine pericardial patches to restore leaflet mobility and coaptation.

• PAPILLARY MUSCLE REPAIR: Realignment or repositioning of displaced papillary muscles (papillary muscle approximation or sling procedures) in ischemic/functional MR to restore subvalvular geometry.

TRANSCATHETER APPROACHES (for high surgical risk patients):

• TRANSCATHETER EDGE-TO-EDGE REPAIR (TEER) — MitraClip (Abbott) / PASCAL (Edwards Lifesciences): A catheter-based procedure performed under general anesthesia and TEE/ICE guidance via transseptal puncture. A clip device is advanced to the mitral valve and grasps the leaflet edges, replicating the Alfieri stitch and reducing MR severity. Approved for both primary (degenerative) MR in prohibitive surgical risk patients and secondary (functional) MR in heart failure patients meeting COAPT trial criteria (LVEF 20–50%, LVESD ≤ 70 mm, optimized medical therapy). Hospital stay: 2–3 days; no sternotomy required; fit-to-fly typically 2–3 weeks.

• TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR): Emerging technology (Tendyne, Intrepid, Tiara systems) for patients with complex anatomy or failed surgical repairs who are not candidates for TEER. Available at highly specialized centers under clinical trial or compassionate use protocols.

INTRAOPERATIVE QUALITY ASSURANCE:

All surgical repairs are assessed in real time using intraoperative transesophageal echocardiography (TEE) immediately after weaning from CPB. Residual MR grade ≥ 2+ or a mean mitral gradient > 5 mmHg on saline testing or post-bypass TEE typically warrants intraoperative revision or conversion to replacement.

PRE-OPERATIVE PHASE (Days 1–3 in destination):

Day 1 — Arrival & Orientation: GAF Healthcare coordinator meets the patient and attendant at the airport. Transfer to pre-arranged hospital-adjacent accommodation or direct hospital admission. GAF case manager provides orientation to the hospital, introduction to the treating cardiac surgeon and cardiologist, and translation support as required.

Day 2 — Diagnostic Workup: Comprehensive pre-operative evaluation including TTE/TEE, 12-lead ECG, Holter monitor, CCTA or coronary angiography (if not already performed in home country), full laboratory panel, PFTs, anaesthesia review, and STS/EuroSCORE II risk calculation. The cardiac surgeon reviews imaging and confirms surgical plan (repair technique, approach — sternotomy vs. mini-thoracotomy vs. robotic). Informed consent discussion with interpreter support.

Day 3 — Pre-operative Preparation: Optimization of any reversible risk factors (glycaemic control, anticoagulation bridging, respiratory physiotherapy instruction). Pre-operative echocardiographic 3D reconstruction and surgical simulation where available. Patient and attendant receive education on post-operative expectations, wound care, and activity restrictions.

INTRAOPERATIVE PHASE (Day 4 — Surgery Day):

• Duration: 3–5 hours (conventional open repair or minimally invasive); 4–6 hours (robotic-assisted or concomitant procedures)

• Anaesthesia: General endotracheal anaesthesia with invasive arterial and central venous monitoring; pulmonary artery catheter in selected cases

• Intraoperative TEE: Real-time echocardiographic guidance throughout the procedure — pre-repair grading, intraoperative anatomical confirmation, post-repair competency assessment, and post-bypass hemodynamic monitoring

• Cardiopulmonary Bypass (CPB) with cold crystalloid or blood cardioplegia for myocardial protection (aortic cross-clamp time typically 60–120 minutes)

• Surgical repair performed per pre-planned technique (resection ± neochordoplasty ± ring annuloplasty) with intraoperative modifications as dictated by operative findings

• Chest closure with mediastinal drains; sternum closed with stainless steel wires (sternotomy) or thoracoscopic port site closure (minimally invasive/robotic)

EARLY POST-OPERATIVE PHASE — CARDIAC ICU (Days 4–6):

• Patient transferred to Cardiac Surgical ICU for hemodynamic monitoring: arterial line, CVP monitoring, continuous telemetry

• Mechanical ventilatory support typically weaned within 4–8 hours of surgery ('fast-track extubation protocol')

• Inotropic support (dopamine, dobutamine, or milrinone) as needed; vasopressor titration

• Mediastinal drains removed at 24–48 hours

• Commencement of anticoagulation: heparin bridging (if mechanical valve implanted, though repair avoids this); aspirin or warfarin for 3 months post-repair with a bioprosthetic ring per institutional protocol; rhythm monitoring for post-operative atrial fibrillation (affects up to 30% of patients transiently)

• Early mobilization: sitting at edge of bed by post-op Day 1; standing with physiotherapy support by Day 2

• Repeat TTE performed before ICU discharge to confirm repair integrity

STEP-DOWN WARD PHASE (Days 6–10):

• Transfer to cardiac step-down or general cardiac ward

• Progressive ambulation: corridor walking by Day 4–5 post-op, stair climbing by Day 6–7

• Cardiac rehabilitation physiotherapy sessions initiated

• Medications confirmed: beta-blocker, ACE inhibitor/ARB (to facilitate LV reverse remodeling), diuretic (to manage volume), and antiarrhythmic if required

• Wound care instruction and sternal/thoracotomy precautions education

• Discharge planning: post-discharge accommodation, follow-up schedule, dietary guidance

• Discharge from hospital: Day 7–10 for uncomplicated cases

POST-DISCHARGE / IN-COUNTRY RECOVERY PHASE (Weeks 2–6):

• Weeks 1–2 post-discharge: Rest at local accommodation; daily wound inspection; avoidance of sternal loading (sternotomy patients: no lifting > 1 kg for 6–8 weeks); light walking recommended

• Week 2: First post-operative outpatient review with surgeon; repeat TTE to confirm repair integrity, assess for pericardial effusion, and document LV remodeling

• Week 3–4: Progressive increase in ambulation; patients with mini-thoracotomy or robotic repair often have greater mobility at this stage

• Week 4: Cardiologist review; ECG and blood tests (INR if on warfarin, renal function, electrolytes); assessment of fitness to fly

• Week 6: Final clearance echocardiogram and cardiologist sign-off. For uncomplicated cases with minimally invasive repair, short-haul flight clearance may be granted at 4 weeks; long-haul international flights are generally cleared at 6 weeks

• Sternal healing: Full sternal union typically requires 6–8 weeks; return to unrestricted physical activity at 8–12 weeks post-sternotomy; 4–6 weeks post-minimally invasive/robotic repair

LONG-TERM FOLLOW-UP:

• Echo surveillance at 1 month, 6 months, 12 months, and annually thereafter

• GAF Healthcare provides telemedicine-enabled follow-up coordination between the treating center and the patient's home cardiologist

• Freedom from reoperation at 10 years: 85–92% for degenerative disease at experienced centers